Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Daily News

CMS Greenlights Reimbursement for Renal Denervation Systems

L.A. McKeown

October 29, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

Presentation TCT 2024

Radiofrequency Renal Denervation in Hypertension – From Symplicity to Iberis HTN

Presenter: Lucas Lauder

October 28, 2024

Presentation TCT 2024

Radiofrequency, Ultrasound, or Alcohol- How Different Are The Devices and What Do I Need To Consider?

Presenter: Tai Kobayashi

October 28, 2024

Presentation TCT 2024

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

Presenter: David Kandzari

October 28, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Daily News

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

L.A. McKeown

August 23, 2023

News Opinion Editor's Corner ESC 2023

What’s Going to Be Hot at ESC 2023?

Shelley Wood

August 15, 2023

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

News Daily News

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

Todd Neale

June 24, 2019

News Daily News

Renal Denervation Lowers BP in Sham-Controlled Studies: Meta-Analysis

Michael O'Riordan

April 02, 2019

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Conference News TCT 2018

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

Todd Neale

September 26, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

News Industry News

Venclose Completes Series B Financing and Announces the Appointment of Jeffrey G. Carr, MD as Chief Medical Officer and Gregory J. Vislocky to its Board of Directors

July 11, 2018

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

News Industry News

Venclose Celebrates 2,000th Procedure with Next-Generation Endovenous Radiofrequency Ablation System

March 20, 2018

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

CMS Greenlights Reimbursement for Renal Denervation Systems

TCTMD’s Top 10 Most Popular Stories for September 2025

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Radiofrequency Renal Denervation in Hypertension – From Symplicity to Iberis HTN

Radiofrequency, Ultrasound, or Alcohol- How Different Are The Devices and What Do I Need To Consider?

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

September 2024 Dispatch for the CV Team

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

What’s Going to Be Hot at ESC 2023?

BP Reduction With Renal Denervation Still Evident a Decade On

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

Renal Denervation Lowers BP in Sham-Controlled Studies: Meta-Analysis

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Venclose Completes Series B Financing and Announces the Appointment of Jeffrey G. Carr, MD as Chief Medical Officer and Gregory J. Vislocky to its Board of Directors

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Venclose Celebrates 2,000th Procedure with Next-Generation Endovenous Radiofrequency Ablation System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content